Enzo IP Suits Against Affy, Roche, Others Move Forward as Court Hands Down Summary Judgment | GenomeWeb

A decade-old string of lawsuits that has embroiled seven life sciences firms is closer to resolution following a recent ruling.

Judge Richard Sullivan of the US District Court of the Southern District of New York on Sept. 21 granted in part and denied in part combined and individual motions from Affymetrix, Amersham, Molecular Probes, Orchid Biosciences, PerkinElmer, and Roche Diagnostics for summary judgment, ruling that they do not infringe IP owned by Enzo Biochem and its wholly owned subsidiary Enzo Life Sciences.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Wired's Sarah Zhang writes that the fight over who developed the CRISPR/Cas9 genome editing tool first underscores the history of parallel discoveries in science.

Recent research indicates that the benefit of having a number of scientists all living and working in a certain area is eroding.

Tomas Lindahl, Paul Modrich, and Aziz Sancar share this year's Nobel Prize in Chemistry for their studies of DNA repair mechanisms.